Anhui Huaren Health Pharmaceutical Co., Ltd. (SHE:301408)
China
· Delayed Price · Currency is CNY 20.99
+0.51 (2.49%)
At close: Apr 29, 2026
SHE:301408 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2019 |
| Net Income | 231.99 | 213.87 | 137.7 | 114.67 | 160.78 | 69.73 | Upgrade
|
| Depreciation & Amortization | 336.6 | 336.6 | 291.11 | 208.75 | 164.52 | 160.66 | Upgrade
|
| Other Amortization | 28.96 | 28.96 | 25.05 | 31.19 | 53.35 | 55.68 | Upgrade
|
| Loss (Gain) From Sale of Assets | -3.74 | -3.74 | -2.72 | -1.04 | -0.61 | -0.19 | Upgrade
|
| Asset Writedown & Restructuring Costs | 94.52 | 94.52 | 17.21 | -0 | 0.01 | -2.72 | Upgrade
|
| Loss (Gain) From Sale of Investments | -5.03 | -5.03 | -1.62 | -0.8 | -0.81 | -0.83 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | -0.08 | 2.26 | 1.03 | 4.39 | Upgrade
|
| Other Operating Activities | -42.87 | 34.02 | 63.02 | 42.74 | 34.81 | 26.46 | Upgrade
|
| Change in Accounts Receivable | -192.25 | -192.25 | 13.1 | -342.08 | -409.81 | -133.86 | Upgrade
|
| Change in Inventory | -97.18 | -97.18 | -17.15 | -179.11 | -113.01 | -131.01 | Upgrade
|
| Change in Accounts Payable | 435.3 | 435.3 | 50.72 | 263.8 | 288.64 | 100.41 | Upgrade
|
| Change in Other Net Operating Assets | - | - | - | - | 1.7 | 0.25 | Upgrade
|
| Operating Cash Flow | 778.41 | 837.18 | 571.76 | 131.37 | 173.84 | 140.82 | Upgrade
|
| Operating Cash Flow Growth | 0.11% | 46.42% | 335.22% | -24.43% | 23.45% | 380.05% | Upgrade
|
| Capital Expenditures | -134.16 | -152.89 | -163.42 | -221.01 | -104.77 | -33.91 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.25 | 0.43 | 2.2 | 5.65 | 0.5 | 0 | Upgrade
|
| Cash Acquisitions | -488.35 | -488.35 | -329.33 | -508.68 | -3.49 | -37.54 | Upgrade
|
| Investment in Securities | 98.81 | -11.83 | -1.83 | -82.92 | -16.77 | 17.11 | Upgrade
|
| Other Investing Activities | 4.73 | 5.49 | 5.44 | 1.14 | -5.43 | 14.25 | Upgrade
|
| Investing Cash Flow | -518.72 | -647.15 | -486.95 | -805.82 | -129.96 | -40.09 | Upgrade
|
| Long-Term Debt Issued | - | 734.35 | 509.49 | 885.56 | 341.9 | 160.76 | Upgrade
|
| Total Debt Issued | 648.51 | 734.35 | 509.49 | 885.56 | 341.9 | 160.76 | Upgrade
|
| Long-Term Debt Repaid | - | -516.68 | -850.95 | -605 | -302.86 | -279.04 | Upgrade
|
| Total Debt Repaid | -405.11 | -516.68 | -850.95 | -605 | -302.86 | -279.04 | Upgrade
|
| Net Debt Issued (Repaid) | 243.4 | 217.66 | -341.45 | 280.57 | 39.05 | -118.28 | Upgrade
|
| Issuance of Common Stock | - | - | - | 974.56 | - | - | Upgrade
|
| Common Dividends Paid | -55.78 | -56.75 | -55.98 | -14.69 | -4.13 | -4.34 | Upgrade
|
| Other Financing Activities | -547.49 | -405.44 | 41.67 | -104.17 | -2.76 | 19 | Upgrade
|
| Financing Cash Flow | -359.91 | -244.52 | -355.77 | 1,136 | 32.15 | -103.62 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.27 | -0.13 | 0.11 | 0.1 | - | - | Upgrade
|
| Net Cash Flow | -100.48 | -54.62 | -270.84 | 461.92 | 76.04 | -2.89 | Upgrade
|
| Free Cash Flow | 644.25 | 684.29 | 408.33 | -89.64 | 69.07 | 106.91 | Upgrade
|
| Free Cash Flow Growth | 3.19% | 67.58% | - | - | -35.40% | - | Upgrade
|
| Free Cash Flow Margin | 11.42% | 12.47% | 9.01% | -2.36% | 2.12% | 4.57% | Upgrade
|
| Free Cash Flow Per Share | 1.62 | 1.72 | 1.01 | -0.23 | 0.20 | 0.32 | Upgrade
|
| Cash Interest Paid | - | - | 0 | 0 | - | - | Upgrade
|
| Cash Income Tax Paid | 250.31 | 221.55 | 210.18 | 186.5 | 151.26 | 106.53 | Upgrade
|
| Levered Free Cash Flow | 573.81 | - | 450.85 | 214.5 | 132.02 | 228.23 | Upgrade
|
| Unlevered Free Cash Flow | 573.81 | - | 470.95 | 232.66 | 146.63 | 243.24 | Upgrade
|
| Change in Working Capital | 137.98 | 137.98 | 42.09 | -266.37 | -239.23 | -172.35 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.